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Abstract
Background: Tuberculosis (TB) is still a global health problem mainly due to development of resistance and co-infection
with the Human immune Virus (HIV). Treatment of multi and extensively drug resistant TB requires use of second line
drugs which are less efficacious, expensive and very toxic. This has necessitated a need to search for new treatment
regimens especially from medicinal plants. Zanthoxylum leprieurii, a plant species from Rutaceae is used locally in the
treatment of tuberculosis in Uganda. The aim of the study was to isolate, identify and characterize bio active compounds
from Z. leprieurii stem bark with antimycobacterial activity.
Methods: Crude extracts, fractions and compounds from air dried stem bark of Z. leprieurii were tested against pan
sensitive (H37rv), isoniazid resistant (TMC 301) and rifampicin resistant (TMC 331) strains of M. tuberculosis using micro
plate alamar blue assay. Isolation of active compounds was done by using column chromatography and thin layer
chromatography. They were analysed using nuclear magnetic resonance spectroscopy and mass spectroscopy.
Results: The methanol extract had minimum inhibitory concentrations (MIC) of 47.5, 75.3 and 125.0 μg/ml on the pan
sensitive strain, rifampicin resistant and isozianid resistant strains of M. tuberculosis respectively. The chloroform extract had
MIC values of 260 μg/ml agnaist the pan sensitive strain and 156 μg/ml on the rifampicin resistant strain. Of the sixteen
fractions from the methanol extract, fraction Za4 (MIC = 6.3 μg/mL, 23.0 μg/mL, 11.7 μg/mL) and Za6 (MIC = 11.7 μg/mL
31.2 μg/ml, 31.2 μg/ml) were the most active. Three acridone alkaloids; hydroxy-1, 3-dimethoxy-10-methyl-9-acridone (1),
1-hydroxy-3-methoxy-10-methyl-9-acridone (2) and 3-hydroxy-1, 5, 6-trimethoxy-9-acridone (3) were isolated from Za4
and Za6. The MIC of compound 3 was found to be 5.1 μg/ml, 4.5 μg/ml and 3.9 μg/ml on H37rv, TMC 331 and TMC 301
while that of 1 was found to be 1.5 μg/ml, 8.3 μg/ml and 3.5 μg/ml respectively.
Conclusion: The results of this study suggest that Z. leprieurii is active on resistant strains of M. tuberculosis and could be a
potential source of new leads against resistant tuberculosis. It also verifies the local use of the plant in treatment of
tuberculosis.
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Background
Mycobacterium tuberculosis, the bacillus that causes
tuberculosis (TB), is one of the leading causes of illness
and death worldwide, accounting for 9.6 million new
cases and 1.5 million deaths per year [1]. Africa carries
the most severe TB burden with a prevalence of 281
cases per 100,000 individuals compared to the global
average of 133/100, 000 [2]. Uganda, one of the high TB
burden countries, reports approximately 166 new cases
per 100,000 people [3]. The high TB burden is attributed
to Human Immune Virus (HIV) co-infection in addition
to development of multi- and extensively drug resistant
strains (MDR and XDR) of TB [3]. Worldwide, MDR TB
was reported to account for 5% of all new tuberculosis
cases [4] of which 9% was caused by XDR-TB [5].
Treatment of resistant strains of MDR TB presents a
challenge globally because it involves use of more than
three drugs for a long period which results in non
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adherence and development of even more resistant strains
[6]. While new drugs like bedaquiline and delamanid have
recently been discovered and approved for use in MDR
TB [7], they are expensive and mostly unavailable in poor
resource countries. Furthermore, discovery of these new
drugs took approximately 40 years since the last new anti
TB drug was introduced. This slow pace in drug develop-
ment in addition to the rapid emergence and spread of
resistant TB calls for continuous search for new agents
that are effective against resistant M. tuberculosis.
Medicinal plants have long been used for treatment of
different ailments in local communities [8]. As such, drugs
like chloroquine, artemisinin derivatives and morphine
have been derived from different plant sources [9].
Zanthoxyllum contains about 549 species distributed
worldwide; making it the largest genus in Rutaceae [10]
Zanthoxyllum leprieurii, a plant species belonging to the
same family, is traditionally used in the treatment of HIV/
AIDS, malaria, urinary infections, rheumatic pain and is
used as an antiseptic in Africa [11, 12]. In addition, it is
used by communities in Uganda for management of TB
and cough related infections [13, 14]. Pharmacological
assessment of Z. leprieurii could potentially lead to the
discovery of new anti-TB agents as well as verify its use
among local people in Uganda communities. The aims of
the study were to; assess the anti mycobacterial activity of
Z. leprieurii, to isolate compounds from Z. leprieurii and
to determine the antimycobacterial activity of the isolated
compounds against a pan sensitive, rifampicin resistant
and isoniazid resistant strains of M. tuberculosis.
Methods
Preparation of plant extract
Stem bark of Z. leprieurii Guill. & Perr (locally called
‘Munyenye’ in luganda) was collected from Mpigi District
in Central Uganda (0° 13′ 38.4708″ N 32° 19′ 29.7264″ E).
With the help of a botanist (Paul Segawa from Makerere
University Herbarium), the plant was identified and voucher
specimen indexed as BL 030 was deposited at the Makerere
University Herbarium. The powdered plant material (500 g)
was weighed and soaked separately in methanol (1000 ml)
and chloroform (1000 ml) for four days with occasional
shaking. The filtrates were concentrated under reduced
pressure using a rotary evaporator to give 13.25 g and




Three preserved strains of M. tuberculosis were used
and they included; a rifampicin resistant strain (TMC
331/ATCC35838), an isoniazid resistant strain (TMC
301/ATCC 35820) and a pan sensitive strain (H37Rv) as
a positive control. All the strains were obtained from
Joint Clinical Research centre (JCRC) Kampala Uganda.
Preparation of inoculums
M. tuberculosis was grown on Middle brook 7H10 agar
for three weeks and then introduced into 7H9 broth
(10 ml) supplemented with 0.2% (v/v) glycerol, oleic
acid, albumin, dextrose, catalase (OADC). The inoculum
was incubated at 37 °C for 24 h. Turbidity equivalent to
0.5 MC Farland standards (1.5*108 CFU) were prepared
using a nephlometer.
Preparation of drugs and plant extracts
The plant crude extracts, fractions, pure compounds and
standard drugs were prepared in either sterile distilled
water or DMSO depending on their solubility. The final
concentrations tested ranged from 0.024- 6.250 μg/ml,
1.9–500 μg/ml and 24.4–6250 μg/ml for compounds/
drugs, fractions and extracts respectively.
Procedure
Susceptibility testing: Micro plate alamar blue assay
(MABA) was used as described by Lawal et al., (2011)
[15]. Sterile distilled water (200 μl) was added to all outer
perimeter wells of sterile 96-well plates to minimize evap-
oration. The remaining wells received 100 μl of 7H9
broth. One hundred micro liters of double concentration
drug solutions were added to each of the wells in rows B
to G in column 2 and serial dilutions were made through
column 10 using a multi channel pipette.
Each of the wells in rows from 2–11 were inoculated
with 100 μl of M. tuberculosis bringing the final volume
to 200 μl per well. The wells in column 11 were drug
free containing only the inoculum and broth and these
acted as negative control wells. The plates were incu-
bated at 37 °C for 24 h. The tests were prepared in tripli-
cate for each of the strains used. Thirty micro liters of a
freshly prepared alamar blue reagent was added to one
of the control wells and further incubated at 37 °C for
24 h. Observation of a color change indicated that there
was growth. The dye was then added to all the wells and
further incubated for 24 h. The minimum inhibitory
concentration (MIC) was defined as the lowest drug
concentration which prevented a color change from blue
to pink (Additional file 1). The bioassays were performed
in a level 3 bio safety laboratory.
Phytochemical testing
The methanolic extract was subjected to silica gel column
chromatography using a gradient system of n-hexane-
AcOEt and AcOEt-MeOH as eluents. Fractions of 250 ml
each were collected and combined on the basis of their
thin layer chromatography profile. Sixteen fractions (Za1-
Za16) were obtained and these were again tested on
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Mycobacterium using the above method. The fractions
which showed the lowest MIC values (i.e. Za4 and Za6)
were isolated using repetitive preparative TLC to obtain
compounds 1, 2 and 3. These were analyzed using inten-
sive 1D and 2D nuclear magnetic resonance (NMR)
spectroscopy.
General experimental procedures
Analytical and Preparative TLC were performed respect-
ively using silica gel 60 PF254 + 366 (Merck) and silica gel
60-F254 precoated aluminum sheets (Merck). The plates
were visualized under UV (254 and 366 nm) and revealed
by spraying with vanillin-sulphuric acid (Additional file 2).
NMR spectra were recorded on Bruker DMX Avance
300 MHz instrument equipped with an auto-tune probe
and using the automation mode aided by chloroform
(CDCl3) as solvent and internal standards.
Results
Antimycobacterial activity of fractions and crude extracts
The MIC values of the methanol crude extract were
47.5 μg/ml, 75.3 μg/ml and 125.0 μg/ml against the pan
sensitive, rifampicin resistant and isoniazid resistant
strains respectively (Table 1). The chloroform crude ex-
tract had MICs of 260.0 μg/ml and 156.3 μg/ml on the
pan sensitive and isoniazid resistant strains respectively.
The methanol extract showed a relatively lower MIC
value as compared to the chloroform extract.
Sixteen fractions from the methanol crude extract were
further tested. The fractions that had MICs ≤ 100 μg/ml
on all the tested strains were; Za1, Za2, Za3, Za4 and Za6
(Table 1). Fraction Za4 had MICs of 6 μg/ml, 23 μg/ml
and 11.7 μg/ml on the pan sensitive, rifampicin resistant
and isoniazid resistant strains respectively. Za6 had MICs
of 11.7 μg/ml on the pan sensitive strain well as on resist-
ant strains its MIC was31.2 μg/ml. The MIC of fractions
Za10-16 was beyond the tested concentration of 500 μg/ml.
Spectral data of isolated compounds
Three compounds, 1-3 (Fig. 1) were isolated from frac-
tions Za4 and Za6 of the methanol extract. Their spectral
data is displayed below (Additional file 3):
Compound 1: yellow needle like crystals (8.2 mg);
1H NMR (300 MHz, CDCl3), δH (m, J in Hertz): 6.32
(s, H-4), 7.55 (brd, J = 9 Hz, H-5), 7.77(ddd, J = 8.7, 6.9,
1.8 Hz, H-6), 7.36 (m, H-7), 8.50(dd, J = 7.8, 1.5 Hz, H-8),
3.89(s, N-CH3), 3.98 (s, 1-OCH3), 4.07 (s, 3-OCH3);
13C NMR (75 MHz, CDCl3): 156.2 (C-1), 130.2 (C-2),
159.4 (C-3), 86.7 (C-4), 140.5 (C-4a), 114.6(C-5),
142.1(C-5a), 134.0 (C-6), 121.5(C-7), 126.7(C-8),
120.8 (C-8a), 180.7 (C-9), 105.9 (C-9a), 34.1(N-CH3),
60.8 (1-OCH3), 56.0 (3-OCH3); ESI-MS ([M]
+ at m/z 285.4) calcd for C16H15NO4
Compound 2: Yellow powder (7.2 mg); 1H NMR
(300 MHz, CDCl3), δH (m, J in Hertz): 6.32(d,
J = 2.1 Hz, H-2), 6.54(d, J = 2.2 Hz, H-4), 7.25
(m, H-5), 7.25 (m, H-6), 7.35 (m, H-7), 8.39
(dd, J = 8.1, 1.6 Hz, H-8), 3.93 (s, N-CH3), 3.97
(s, 3-OCH3);
13C NMR (75 MHz, CDCl3): 165.3
(C-1), 89.6 (C-2), 166.3 (C-3), 89.5 (C-4), 142.5
(C-4a), 115.4 (C-5), 145.0 (C-5a), 134.1 (C-6),
121.2 (C-7), 126.9 (C-8), 120.7 (C-8a), 180.4 (C-9),
104.8 (C-9a), 33.8 (N-CH3), 55.2 (3-OCH3);
ESI-MS([M]+ at m/z 255.3) calcd for C15H13NO3
Compound 3: Orange powder (5.0 mg); 1H NMR
(300 MHz, CDCl3), δH (m, J in Hertz): 8.07(d, J = 9.6 Hz,
H-8), 7.64 (d, J = 2.7 Hz, H-4) 7.29 (d, J = 9.6 Hz, H-7)
7.10 (d, J = 2.7Hz, H-2), 4.49 (s, 5-OCH3), 4.17
(s, 1-OCH3), 4.08 (s, N-H); 13C NMR (75 MHz,
CDCl3): 157.3 (C-1), 102.1 (C-2), 164.3 (C-3), 104.7
(C-4), 143.1 (C-4a), 141.4 (C-5), 142.0 (C-5a), 152.2
(C-6), 112.2 (C-7), 118.2 (C-8), 115.0 (C-8a), 185.1
(C-9), 104.7 (C-9a), 59.1 (1- OCH3), 61.7 (5-OCH3),
56.9 (6-OCH3)
Antimycobacterial activity of compounds
Compound 1, 2 and 3 were screened for activity against
M. tuberculosis. Compound 1 had MICs of 1.5 μg/ml,
3.5 μg/ml and 8.3 μg/ml on the pan sensitive, isoniazid
Table 1 Mean MIC values of extracts and fractions from Z.














Za1 31.3 31.3 78.2
Za2 94.5 31.3 63.2
Za3 >500 16.4 >500
Za4 6.3 23.0 11.7
Za5 31.3 31.3 94.1
Za6 11.7 31.3 31.3
Za7 94.1 94.1 >500
Za8 63.2 31.3 >500
Za9 63.2 >500 >500
aZa 10 >500 >500 >500
Rifampicin 2.0 - 2.0
Isoniazid 4.0 4.0 -
aZa 10 = Za11−Za16 with MIC >500 ug/ml
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resistant and rifampicin resistant strains respectively
(Table 2). Compound 3 had MICs of 5.1 μg/ml, 4.5 μg/
ml and 3.9 μg/ml on the pan sensitive, isoniazid resistant
and rifampicin resistant strains of M. tuberculosis
respectively while the MIC of compound 2 was beyond
the tested concentration, 6.250 μg/ml.
Discussion
>The search for new anti TB drugs is continuing to be
the focus for most research globally due to development
of multi drug and extensively drug resistant strains of
M. tuberculosis. Although drugs like bedaquiline and
delamanid have recently been discovered and are used in
treatment of MDR TB [7], they are equally expensive and
unavailable in poor resource countries. Furthermore re-
ports of totally drug resistant TB in countries like India
and South Africa are threatening to make the disease
untreatable [16, 17]. In this study, the anti mycobacterial
activity of the crude extracts, fractions and compounds
from Z. leprieurii were evaluated to help demonstrate the
plant’s potential as an alternative source for new anti TB
agents. The extracts/fractions were considered to be active
if the MICs were ≤ 100 μg/ml [18, 19] while the pure com-
pounds were considered to have antimycobacterial activity
if their MIC ≤ 6.25 μg/ml; the maximum tested concentra-
tion. In the same way an extract, fraction or compound
was considered not to be active if the MIC value was
beyond the tested concentration.
Both crude extracts from Z. leprieurii showed some
inhibitory activity with the methanol extract being more
active against all the M. tuberculosis strains as compared
to the chloroform extract. This could be due to numerous
compounds extracted by methanol which is believed to be
an efficient solvent during extraction [20–22]. The metha-
nol extract was fractionated and fractions Za4 and Za6
were the most active against all the tested strains; implying
that they could possibly contain compounds which could
be active on MDR TB warranting further phytopharmaco-
logical analysis. However, the activity of the crude extracts
was generally lower than that of the pure drugs; isoniazid
and rifampicin. The low anti-TB inhibition exhibited by
the crude extracts could be due to presence of impurities
which may interfere with and reduce the potency of the
extracts [23]. Over all, purification of Z. leprieurii
methanol extract yielded fractions that showed substantial
activity than the crude extracts especially against the
pan sensitive strain. Among these, fraction Za4 (MIC
= 6.3 μg/ml) was seven times more potent than the
methanol crude extract (MIC = 47.5 μg/ml).
Three known acridone alkaloids that is; 2-hydroxy-1,
3-dimethoxy-10-methyl-9-acridone (1), 1-hydroxy-3-
methoxy-10-methyl-9-acridone (2) and 3-hydroxy-1, 5,
6-trimethoxy-9-acridone (3) were isolated from fractions
Za4 and Za7. Their structures were confirmed by analyz-
ing their spectral data and also through comparison with
already published work [24–26]. When screened for anti
mycobacterial activity, compound 1 was found to have a
lower MIC value (MIC = 1.5 μg/ml) than both isoniazid
(MIC = 0.2 μg/ml) and rifampin (MIC = 0.4 μg/ml); two
first line drugs that form a backbone in TB treatment
[27]. This shows that there is potential for further devel-
opment of compound 1 into new anti TB agents that
could be an alternative to the two most important first
line drugs in TB treatment. On the contrary, Compound 2
was inactive on M. tuberculosis. The variation in activity
could not be verified in this study however it is thought
Fig. 1 Chemical structure of compounds 1, 2 and 3
Table 2 Mean MIC Values of isolated compounds 1, 2 and 3 on
three strains of M. tuberculosis







1 1.5 ± 0.8 5.9 ± 3.2 3.2 ± 1.7
2 >6.250 >6.250 >6.250
3 5.1 ± 1.1 4.1 ± 0.0 3.9 ± 0.6
Isoniazid 2.0 ± 0.0 4.0 ± 2.1 -
Rifampicin 4.0 ± 0.0 - 2.0 ± 0.0
± Standard deviation
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that it could be linked to the number and positions of
hydroxyl and methoxy groups on rings A and B. Previous
studies have shown that the antimycobacterial activity of
alkaloids is affected by the number and positions of func-
tional groups [28].
Previous studies done on Cameroonian spices revealed
that Z. xanthoxyloides and Z. macrophylla showed weak
activity with MICs of 1.024 mg/ml against H37Rv and
H37Ra [29]. However a study by Luo et al., [30] showed
that extracts from Z. capense had antimycobacterial activity.
In addition, decarine, a benzophenanthridine alkaloid was
isolated and found to inhibit growth of M. tuberculosis
within macrophages with MIC of 1.6 μg/ml on the pan
sensitive strain. Compound 3 has been shown to have
cytotoxic effects (IC50 of 86 μM) against liver cancer cell
lines by inhibiting glycosyltransferase and aromatase
enzymes in the liver [31]. In addition compound 2 had a
moderate activity of 33% mortality against Anopheles
gambiae larvae at a concentration of 1000 ppm [31]. In a
review by Kishore et al., (2009) [32], different types of
alkaloids have been shown to have anti mycobacterial
activity however no study has reported activity of acri-
done alkaloids on resistant strains of TB. Our results add
to other plant derived compounds from genus Zanthoxyl-
lum which could be further explored as anti TB agents.
Conclusion
Our results show that Pharmacological assessment of
Z. leprieurii could potentially lead to the discovery of new
anti TB agents. Bioassay guided isolation of Z. leprieurii
afforded three acridone alkaloids; two of which showed
activity on M. tuberculosis resistant strains. These findings
also provide some scientific evidence to support, to some
extent, the ethnomedicinal use of Z. leprieurii as traditional
antitubercular remedies in Uganda communities though
more studies on the in-vivo antimycobacterial activity and
toxicity of the bio active compounds is needed.
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